Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 12
Venture Financing 14
Civitas Therapeutics Raises USD55 Million in Series C Financing 14
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 16
Civitas Therapeutics Secures US$5 Million In Venture Financing 18
Civitas Therapeutics Secures An Additional US$8 Million In Series A Financing Round 19
Partnerships 20
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
Licensing Agreements 22
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Acorda Therapeutics Enters Into Licensing Agreement With Medtronic For AC105 23
Equity Offering 24
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 24
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 25
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 26
Civitas Therapeutics Withdraw IPO for up to USD80 million 28
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 29
Biotie Therapies Completes Private Placement Of Treasury Shares For US$37.4 Million 30
Debt Offering 31
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 31
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 33
Acquisition 35
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Acorda Therapeutics Completes Acquisition Of Neuronex For Up To US$141 Million 40
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 42
Biotie Therapies Acquires Synosia Therapeutics 43
Acorda Therapeutics Inc – Key Competitors 46
Acorda Therapeutics Inc – Key Employees 47
Acorda Therapeutics Inc – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 50
Strategy And Business Planning 50
Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 50
Financial Announcements 51
Oct 31, 2017: Acorda Provides Financial and Pipeline Update for Third Quarter 2017 51
Jul 27, 2017: Acorda Provides Financial and Pipeline Update for Second Quarter 2017 53
Apr 27, 2017: Acorda Provides Financial and Pipeline Update for First Quarter 2017 55
Feb 14, 2017: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 57
Oct 27, 2016: Acorda Provides Financial and Pipeline Update for Third Quarter 2016 59
Jul 28, 2016: Acorda Provides Financial and Pipeline Update for Second Quarter 2016 61
Apr 28, 2016: Acorda Provides Financial and Pipeline Update for First Quarter 2016 63
Feb 11, 2016: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2015 65
Corporate Communications 67
Feb 21, 2017: Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors 67
Apr 10, 2016: Acorda Announces Departure of Michael Rogers 68
Product News 69
04/05/2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 69
Product Approvals 70
Aug 26, 2016: Biotie: BTT1023 Receives Orphan Drug Designation in the United States 70
Clinical Trials 71
Jun 06, 2017: Acorda Presenting New Tozadenant Data at 2017 MDS Congress 71
Mar 29, 2017: Acorda Announces Long-Term Safety Data for CVT-301 72
Feb 09, 2017: Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 74
Oct 13, 2016: Data from Clinical and Preclinical Trials of CVT-301 for Treatment of OFF Periods in Parkinsons Disease Published in Science Translational Medicine 76
Apr 20, 2016: Acorda Announces Results from Phase 2b Clinical Trial of CVT-301 for Treatment of OFF Periods in Parkinson’s Disease Published in Movement Disorders 77
Apr 07, 2016: Phase 2b Data on Inhaled Levodopa CVT-301 Featured in Invited Science Session at American Academy of Neurology (AAN) Annual Meeting 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acorda Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 12
Civitas Therapeutics Raises USD55 Million in Series C Financing 14
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 16
Civitas Therapeutics Secures US$5 Million In Venture Financing 18
Civitas Therapeutics Secures An Additional US$8 Million In Series A Financing Round 19
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Acorda Therapeutics Enters Into Licensing Agreement With Medtronic For AC105 23
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 24
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 25
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 26
Civitas Therapeutics Withdraw IPO for up to USD80 million 28
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 29
Biotie Therapies Completes Private Placement Of Treasury Shares For US$37.4 Million 30
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 31
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 33
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Acorda Therapeutics Completes Acquisition Of Neuronex For Up To US$141 Million 40
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 42
Biotie Therapies Acquires Synosia Therapeutics 43
Acorda Therapeutics Inc, Key Competitors 46
Acorda Therapeutics Inc, Key Employees 47
Acorda Therapeutics Inc, Subsidiaries 48